Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scynexis, PharmaDirections and TAU Therapeutics have jointly developed an API synthetic process for mibefradil to help TAU commence its Phase 1 clinical trials.
Subscribe to our email newsletter
Mibefradil, used for cancer treatment, is a T-type calcium channel blocker which arrests tumor cells at their most vulnerable metabolic point.
TAU Therapeutics is developing Mibefradil.
Scynexis and PharmaDirections have involved in the process and analytical development and GMP manufacturing of mibefradil since 2010.
The companies worked on minimizing or eliminating the impurities found in the original manufacturing process.